Richter syndrome: Pathogenesis and management

Seminars in Oncology

Volumn 43, Issue 2, 2016, Pages 311-319

  Rossi, Davide ^a   Gaidano, Gianluca ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Chronic lymphocytic leukemia; Diffuse large B cell lymphoma; NOTCH1; Richter syndrome; Subset 8

Indexed keywords

ANTILEUKEMIC AGENT; NEW DRUG; SELINEXOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; GENETIC BACKGROUND; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MOLECULAR PATHOLOGY; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RICHTER SYNDROME; STEM CELL TRANSPLANTATION; SYNDROME; CELL TRANSFORMATION; DISEASE COURSE; DISEASE MANAGEMENT; GENETICS; HODGKIN DISEASE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; DISEASE PROGRESSION; HODGKIN DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREVALENCE; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84959525298     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2016.02.012     Document Type: Review

References (66)

1. H.K. Müller-Hermelink, E. Montserrat, D. Catovsky, E. Campo, N.L. Harris, and H. Stein Chronic lymphocytic leukemia/small lymphocytic lymphoma S.H. Swerdlow, E. Campo, N.L. Harris, World Health Organization classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues 2008 Lyon: IARC 180 182
2. Z. Mao, L. Quintanilla-Martinez, M. Raffeld, and et al. IgVH mutational status and clonality analysis of Richter's transformation Am J Surg Pathol 31 2007 1605 1614
3. D. Rossi, V. Spina, M. Cerri, and et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome Clin Cancer Res 15 2009 4415 4422
4. D. Rossi, V. Spina, C. Deambrogi, and et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation Blood 117 2011 3391 3401
5. E. Giné, A. Martinez, N. Villamor, and et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia («accelerated» chronic lymphocytic leukemia) with aggressive clinical behavior Haematologica 95 2010 1526 1533
6. A.M. Tsimberidou, S. O'Brien, H.M. Kantarjian, and et al. Hodgkin transformation of chronic lymphocytic leukemia: The M. D. Anderson Cancer Center experience Cancer 107 2006 1294 1302
7. B. Bockorny, I. Codreanu, and C.A. Dasanu Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: A retrospective analysis of world literature Br J Haematol 156 2012 50 66
8. T. Ohno, B.N. Smir, D.D. Weisenburger, R.D. Gascoyne, S.D. Hinrichs, and W.C. Chan Origin of the Hodgkin/Reed-Sternberg cells in chronic lymphocytic leukemia with Hodgkin's transformation Blood 91 1998 1757 1761
9. A. van den Berg, E. Maggio, R. Rust, K. Kooistra, A. Diepstra, and S. Poppema Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma Blood 100 2002 1425 1429
10. L. de Leval, M. Vivario, B. De Prijck, and et al. Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated With EBV infection Am J Surg Pathol 28 2004 679 686
11. M.J. Keating, S. O'Brien, S. Lerner, and et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy Blood 92 1998 1165 1171
12. S. Tabuteau, J. Fernandez, R. Garidi, and B. Desablens Richter's syndrome in B-CLL: Report of 37 cases Blood (ASH Annual Meeting Abstracts) 34 Suppl 1 1999 306b
13. F.R. Mauro, R. Foa, D. Giannarelli, and et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: A single institution study of 204 cases Blood 94 1999 448 454
14. T Robak, JZ Blonski, J. Gora-Tybor, and et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine Eur J Cancer 40 2004 383 389
15. P.D. Thornton, C. Bellas, A. Santon, and et al. Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis Leukemia Res 29 2005 389 395
16. K. Maddocks-Christianson, S.L. Slager, C.S. Zent, and et al. Risk factors for development of a second malignancy in patients with chronic lymphocytic leukaemia Br J Haematol 139 2006 398 404
17. A.-M. Tsimberidou, S. O'Brien, I. Khouri, and et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation J Clin Oncol 24 2006 2343 2351
18. D. Catovsky, S. Richards, E. Matutes, and et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial Lancet 370 2007 230 239
19. S. Alipour, H. Leiitch, L.M. Vickars, and et al. Richter transformation of chronic lymphocytic leukemia: Incidence, risk factors and outcome Blood (ASH Annual Meeting Abstracts) 112 2008 3179
20. D. Rossi, M. Cerri, D. Capello, C. Deambrogi, and et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome Br J Haematol 142 2008 202 215
21. K. Fischer, J. Bahlo, A.M. Fink, and et al. Extended follow up of the CLL8 protocol, a randomized phase-III trial of the German CLL Study Group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): Results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen Blood (ASH Annual Meeting Abstracts) 120 2012 435
22. J.C. Byrd, R.R. Furman, S.E. Coutre, and et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia N Engl J Med 369 2013 32 42
23. S.A. Parikh, K.G. Rabe, T.G. Call, and et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): A cohort study of newly diagnosed patients Br J Haematol 162 2013 774 782
24. M. Solh, K.R. Rai, B.L. Peterson, and et al. The impact of initial fludarabine therapy on transformation to Richter's syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: Analysis of an intergroup trial (CALGB 9011) Leuk Lymphoma 54 2013 252 254
25. O. Benjamini, P. Jain, L. Trinh, and et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: Distribution and clinical outcomes Leuk Lymphoma 56 2015 1643 1650
26. J.C. Byrd, J.R. Brown, S. O'Brien, and et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia N Engl J Med 371 2014 213 223
27. S. O'Brien, R.R. Furman, S.E. Coutre, and et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial Lancet Oncol 15 2014 48 58
28. P. Strati, M.J. Keating, S.M. O'Brien, and et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion Haematologica 99 2014 1350 1355
29. M.Z. Farooqui, J. Valdez, S. Martyr, and et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial Lancet Oncol 16 2015 169 176
30. P. Jain, M. Keating, W. Wierda, and et al. Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib Blood 125 2015 2062 2067
31. S.A. Parikh, T.M. Habermann, K.G. Chaffee, and et al. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma Am J Hematol 90 2015 334 338
32. S. Aydin, D. Rossi, L. Bergui, and et al. CD38 gene polymorphism and chronic lymphocytic leukemia: A role in transformation to Richter syndrome? Blood 111 2008 5646 5653
33. S. Rasi, V. Spina, A. Bruscaggin, and et al. A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome Br J Haematol 152 2011 284 294
34. S.A. Parikh, S.L. Slager, K.G. Rabe, N.E. Kay, J.R. Cerhan, and T.D. Shanafelt Heritable predisposition to Richter syndrome in patients with chronic lymphocytic leukemia Blood (ASH Annual Meeting Abstracts) 122 2013 2867
35. D. Rossi, S. Rasi, G. Fabbri, and et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia Blood 119 2012 521 529
36. D. Rossi, S. Rasi, V. Spina, and et al. Different impact of NOTCH1and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome Br J Haematol 158 2012 426 429
37. N. Villamor, L. Conde, A. Martínez-Trillos, and et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome Leukemia 27 2013 1100 1106
38. S.M. O'Brien, H.M. Kantarjian, D.A. Thomas, and et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia Cancer 98 2003 2657 2663
39. C. Karlsson, S. Norin, E. Kimby, and et al. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: Long-term follow-up of clinical effects, infectious complications and risk of Richter transformation Leukemia 20 2006 2204 2207
40. H.C. Kluin-Nelemans, J.L. Coenen, J.E. Boers, G.W. van Imhoff, and S. Rosati EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma Blood 112 2008 1039 1041
41. S. Lepretre, T. Aurran, B. Mahé, and et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial Blood 119 2012 5104 5110
42. G. Fabbri, H. Khiabanian, A.B. Holmes, and et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome J Exp Med 210 2013 2273 2288
43. D. Rossi, V. Spina, F. Forconi, and et al. Molecular history of Richter syndrome: Origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis Int J Cancer 130 2012 3006 3010
44. E. Chigrinova, A. Rinaldi, I. Kwee, and et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome Blood 122 2013 2673 2682
45. D. Rossi, E. Berra, M. Cerri, and et al. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma Haematologica 91 2006 1405 1409
46. L. de Paoli, M. Cerri, S. Monti, and et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia Leuk Lymphoma 54 2013 1087 1090
47. A. Cascón, and M. Robledo MAX and MYC: A heritable breakup Cancer Res 72 2012 3119 3124
48. G. Fabbri, S. Rasi, D. Rossi, V. Trifonov, H. Khiabanian, J. Ma, and et al. Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation J Exp Med 208 2011 1389 1401
49. X.S. Puente, M. Pinyol, V. Quesada, L. Conde, G.R. Ordóñez, N. Villamor, and et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia Nature 475 2011 101 105
50. C. Lobry, P. Oh, and I. Aifantis Oncogenic and tumor suppressor functions of Notch in cancer: It's NOTCH what you think J Exp Med 208 2011 1931 1935
51. F. Arruga, B. Gizdic, S. Serra, and et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia Leukemia 28 2014 1060 1070
52. M. López-Guerra, S. Xargay-Torrent, L. Rosich, and et al. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells Leukemia 29 2015 96 106
53. M. Gounari, S. Ntoufa, C.C. Chu, and et al. Promiscuous antigen reactivity may underlie clinical aggressiveness and increased risk for Richter's syndrome in chronic lymphocytic leukemia with stereotyped IGHV4-39/IGKV1(D)-39 B cell receptors Blood (ASH Annual Meeting Abstracts) 120 2012 561
54. J.F. Bruzzi, H. Macapinlac, A.M. Tsimberidou, and et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT J Nucl Med 47 2006 1267 1273
55. P. Langerbeins, R. Busch, N. Anheier, and et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation Am J Hematol 89 2014 E239 E243
56. A.M. Tsimberidou, W.G. Wierda, W. Plunkett, and et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia J Clin Oncol 26 2008 196 203
57. A.M. Tsimberidou, W.G. Wierda, S. Wen, and et al. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome Clin Lymphoma Myeloma Leuk 13 2013 568 574
58. B.S. Dabaja, S.M. O'Brien, H.M. Kantarjian, and et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyper-CVXD) regimen in Richter's syndrome Leuk Lymphoma 42 2001 329 337
59. A.M. Tsimberidou, H.M. Kantarjian, J. Cortes, and et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte macrophage- colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GMCSF in patients with Richter syndrome or fludarabine refractory chronic lymphocytic leukemia Cancer 97 2003 1711 1720
60. A.M. Tsimberidou, S.M. O'Brien, J.E. Cortes, and et al. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders Leuk Lymphoma 43 2002 767 772
61. A.M. Tsimberidou, J.L. Murray, S. O'Brien, W.G. Wierda, and M.J. Keating Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome Cancer 100 2004 2195 2200
62. K. Cwynarski, A. van Biezen, L. de Wreede, and et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation J Clin Oncol 30 2012 2211 2217
63. K. Parikh, S. Cang, A. Sekhri, and D. Liu Selective inhibitors of nuclear export (SINE) - A novel class of anti-cancer agents J Hematol Oncol 7 2014 78
64. J. Kuruvilla, J.C. Byrd, J.M. Flynn, and et al. The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed/refractory non Hodgkin's lymphoma (NHL) Blood (ASH Annual Meeting Abstracts) 124 2014 396
65. T. Tadmor, L. Shvidel, O. Bairey, and et al. Richter's transformation to diffuse large B-cell lymphoma: A retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group Am J Hematol 89 2014 E218 E222
66. T. Tadmor, L. Shvidel, N. Goldschmidt, and et al. Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group Anticancer Res 34 2014 785 790